arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Seres Therapeutics, Inc.

MCRB
$4.83 ▲ +0.02 (+0.42%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
51 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Bullish
auto_awesome

Analytical Summary

Seres Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $46.3M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -62.3%
FCF / Share $-1.71
Trailing P/E
Price / Book 1.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

51-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$358.00K
↓ -18.3%
Net Income Profit after all expenses
$-19.91M
↓ -29.9%
Operating Margin Operating profit as % of sales
29.3%
↓ -25.1%
FCF / Share Free cash flow per share
$-1.71
↓ -780.3%
Long-Term Debt Long-term obligations
$110.00M
— 0.0%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
100
Returns
76
Cash Quality
28

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 51 quarters